Orchestra BioMed Inc. (OBIO)
Orchestra BioMed Statistics
Share Statistics
Orchestra BioMed has 38.31M shares outstanding. The number of shares has increased by 6.22% in one year.
Shares Outstanding | 38.31M |
Shares Change (YoY) | 6.22% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 26.92M |
Failed to Deliver (FTD) Shares | 48 |
FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 736.73K, so 1.94% of the outstanding shares have been sold short.
Short Interest | 736.73K |
Short % of Shares Out | 1.94% |
Short % of Float | 2.79% |
Short Ratio (days to cover) | 4.06 |
Valuation Ratios
The PE ratio is -2413.54 and the forward PE ratio is -2.79. Orchestra BioMed's PEG ratio is 24.16.
PE Ratio | -2413.54 |
Forward PE | -2.79 |
PS Ratio | 55831.75 |
Forward PS | 6.7 |
PB Ratio | 4468.84 |
P/FCF Ratio | -2896.61 |
PEG Ratio | 24.16 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Orchestra BioMed.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.27, with a Debt / Equity ratio of 0.07.
Current Ratio | 4.27 |
Quick Ratio | 4.26 |
Debt / Equity | 0.07 |
Debt / EBITDA | -0.03 |
Debt / FCF | -0.04 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $37.69K |
Profits Per Employee | $-871.77K |
Employee Count | 70 |
Asset Turnover | 0.03 |
Inventory Turnover | 1.18 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -36.22% in the last 52 weeks. The beta is 0.62, so Orchestra BioMed's price volatility has been higher than the market average.
Beta | 0.62 |
52-Week Price Change | -36.22% |
50-Day Moving Average | 4.76 |
200-Day Moving Average | 5.67 |
Relative Strength Index (RSI) | 32.08 |
Average Volume (20 Days) | 62.57K |
Income Statement
In the last 12 months, Orchestra BioMed had revenue of 2.64M and earned -61.02M in profits. Earnings per share was 0.
Revenue | 2.64M |
Gross Profit | 2.43M |
Operating Income | -64.3M |
Net Income | -61.02M |
EBITDA | -64.3M |
EBIT | n/a |
Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 22.26M in cash and 2.24M in debt, giving a net cash position of 20.02M.
Cash & Cash Equivalents | 22.26M |
Total Debt | 2.24M |
Net Cash | 20.02M |
Retained Earnings | -309.88M |
Total Assets | 76.17M |
Working Capital | 52.96M |
Cash Flow
In the last 12 months, operating cash flow was -50.56M and capital expenditures -289K, giving a free cash flow of -50.85M.
Operating Cash Flow | -50.56M |
Capital Expenditures | -289K |
Free Cash Flow | -50.85M |
FCF Per Share | 0 |
Margins
Gross margin is 92.27%, with operating and profit margins of -2437.49% and -2313.27%.
Gross Margin | 92.27% |
Operating Margin | -2437.49% |
Pretax Margin | -2313.27% |
Profit Margin | -2313.27% |
EBITDA Margin | -2437.49% |
EBIT Margin | -2437.49% |
FCF Margin | -1927.48% |
Dividends & Yields
OBIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for OBIO is $14.5, which is 357.4% higher than the current price. The consensus rating is "Buy".
Price Target | $14.5 |
Price Target Difference | 357.4% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Scores
Altman Z-Score | -5.88 |
Piotroski F-Score | 3 |